SUMMARY:``Immunological discordance,'' i.e., immunological failure despite complete viral suppression in human immunodeficiency virus (HIV)-infected patients receiving antiretroviral therapy (ART), is associated with increased risk of AIDS or death. To evaluate risk factors for immunological discordance in a resource-limited setting in which patients usually present late with low CD4 cell counts, we conducted a case-control study among HIV-infected patients receiving ART and having undetectable HIV RNA. The study included patients with immunological discordance (cases), which was defined as CD4 cell count ＜ 30z above baseline and absolute CD4 cell count ＜ 200 cells/mm 3 at the first 12 months of undetectable HIV RNA (＜50 copies/mL). Patients without immunological discordance were included as controls. Of 142 patients (44 cases; 98 controls), the mean age was 38.6 ± 9.4 years and 67.6z were men; 65.5z had history of opportunistic infections. In multivariate analysis, only baseline CD4 cell count ＜ 100 cells/mm 3 (odd ratio [OR], 2.53; 95z confidence interval [CI], 1.04-6.14; P ＝ 0.040) and history of lost to follow-up (OR, 11.04; 95z CI,; P ＜ 0.001) were significantly associated with immunological discordance. Early initiation of ART and intervention to improve regular clinic visit compliance and adherence to ART are crucial to prevent immunological discordance among HIV-infected patients.
INTRODUCTION
Human immunodeficiency virus (HIV) infection is a major health problem globally and in Thailand. The Joint United Nations Programme on HIV/AIDS (UNAIDS) reports that an estimated 530,000 people with HIV currently live in Thailand, and prevalence is estimated at 1.3z (1) . More than 150,000 patients have been treated with antiretroviral therapy (ART) under the National AIDS Program in Thailand (2) . As in other developing countries, many patients present late with low CD4 cell counts (3) . Initiation of ART has significantly improved AIDS-free survival secondary to complete viral suppression and immune reconstitution. However, some patients fail to achieve a significant increase in circulating CD4 cell count despite undetectable plasma HIV RNA. These patients are considered to have immunological failure in spite of complete viral suppression and the condition is referred to as``immunological discordance.'' Previous clinical studies have demonstrated that the prevalence of immunological discordance to ART ranges from 7z to 29z (4) .
Published data on the impact of immunological failure in both high-income and resource-limited countries has indicated that immunological failure is associated with intermediate risk of death or clinical progression to AIDS when compared to complete response (complete viral suppression and successful immune reconstitution) (5-9). Several factors, including previous treatment failure, duration of ART, low CD4 cell count at the initiation of ART, advanced stage of HIV disease, low adherence to ART, and treatment interruption, may affect immunological response in patients receiving ART (4, 10, 11) . In Thailand, where a large number of HIV-infected patients are treated and ART is often initiated at low CD4 cell counts owing to patients' late presentation, there is no published data on risk factors for immunological discordance. Thus, we conducted a study to evaluate factors associated with immunological discordance in HIV-infected patients receiving ART.
METHODS
A case-control study was conducted among HIVinfected adult patients receiving ART and having complete viral suppression between January 1, 2005 and November 30, 2010 in a medical school hospital in Thailand. All subjects had documented HIV infections and met the following criteria: (i) greater than 15 years of age; (ii) scheduled for regular clinical and laboratory visits until the end of the study period; (iii) had achieved undetectable HIV RNA. Patients were excluded if they had (i) a history of treatment interruption and (ii) less than 6 months of follow-up following initiation of ART.
The study included patients with immunological discordance (cases), which was defined as sustained undetectable HIV RNA during ART and CD4 cell count less than 30z above baseline and absolute CD4 cell count ＜ 200 cells/mm 3 at the first 12 months of com-plete viral suppression. The window for CD4 measurement at 12 months was ±1 month. To identify cases of immunological discordance, all patients who had CD4 cell count ＜ 200 cells/mm 3 were screened. Patients without immunological discordance were randomly assigned from the same medical school hospital and included as controls in the study.
Risk factors and baseline characteristics including age, gender, body weight, hepatitis B virus (HBV) coinfection, hepatitis C virus (HCV) co-infection, positive Venereal Disease Research Laboratory (VDRL) test result, underlying diseases, previous opportunistic infections, baseline CD4 cell count, ART regimen, use of co-trimoxazole, change in CD4 cell count, and HIV RNA were obtained from medical records. Patients were deemed``lost to follow-up'' if contact with them during the 1-year period of the study was interrupted for more than 1 month but less than 6 months. The study was approved by the institutional ethics committee.
All analyses were performed using an electronic database organized in SPSS version 16.0. Mean values (±standard deviations [SD] ) and median values (with interquartile range [IQR]) were used to describe the continuous data with and without normal distribution, respectively. Proportion and percent were used to describe the categorical data. Student t-test and the Mann-Whitney U test were used to compare continuous data between the two groups. Chi-square test and Fisher's exact test were used to compare categorical data between the 2 groups. Factors associated with immunological discordance were analyzed using univariate and multivariate approaches. Results are presented as odds ratios (OR) with 95z confidence intervals (CI). A P value of ＜0.05 was considered statistically significant.
RESULTS
A total of 142 patients (44 cases and 98 controls) were studied. Baseline characteristics of all patients are presented in Table 1 . Mean ± SD age was 38.6 ± 9.4 years, and 96 (67.6z) patients were male. HBV coinfection and HCV co-infection were 9.2z and 8.8z, respectively. Risks for HIV infection were heterosexuality (40.9z), homosexuality (25.0z), and intravenous drug use (13.6z); and the rest could not be determined. Of all patients, 65.5z had a history of major opportunistic infection, of which tuberculosis was the most common (33.8z). ART regimens included non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (93.7z), protease inhibitor (PI)-based (4.2z), and others (2.1z). At mean ± SD follow-up duration of 10.9 ± 3.6 months, median CD4 cell count in the case group was significantly lower than that in the control group (146 vs. 369 cells/mm 3 , P ＜ 0.001).
The case group had higher rates of co-morbid underlying diseases (65.9z vs. 24.5z, P ＜ 0.001), CDC stage C (97.7z vs. 77.6z, P ＝ 0.002), and loss to follow-up (27.3z vs. 4.1z, P ＜ 0.001); lower baseline CD4 cell count (42 vs. 65 cells/mm 3 , P ＝ 0.017); and a trend toward higher rates of using co-trimoxazole for pneumocystis pneumonia prophylaxis (71.4z vs. 53.1z, P ＝ 0.061) than the control group. Demographic factors, history of tuberculosis, use of zidovudine, and HIV RNA level were not different between the 2 groups (P ＞ 0.05).
In univariate analysis, presence of co-morbid underlying diseases, CDC stage C, use of co-trimoxazole, baseline CD4 cell count, and history of loss to follow-up were significantly associated with immunological discordance. In multivariate analysis, only baseline CD4 cell count ＜ 100 cells/mm 3 (OR, 2.53; 95z CI, 1.04-6.14; P ＝ 0.040) and history of loss to follow-up (OR, 11.04; 95z CI, 2.87-42.46; P ＜ 0.001) were significantly associated with immunological discordance (Table 2) .
DISCUSSION
Immunological failure among HIV-infected patients receiving ART with complete viral suppression, or immunological discordance, is clinically important since it is associated with risk of clinical progression to AIDS or death (5-9). Taiwo et al. previously showed that a CD4 cell count of 200 cells/mm 3 at the time of viral suppression was associated with increased risk of AIDS or death with a hazard ratio of 10.7 when compared to those with a CD4 cell count ＞350 cells/mm 3 (9) . Thus, identifying HIV-infected patients at risk for immunological discordance in clinical care is helpful so that atrisk patients can be carefully monitored to help prevent this condition.
The results from the present study have demonstrated that low baseline CD4 cell count, particularly ＜ 100 cells/mm 3 , and history of loss to follow-up are risk factors for immunological discordance. This finding supports the recommendation of the recently revised 2010 Thai national guidelines that ART should begin earlier, at CD4 cell count of ＜ 350 cells/mm 3 (2) . This recommendation differs from the previous 2008 Thai national guidelines, which recommended initiation of ART at CD4 cell counts ＜ 200 cells/mm 3 (12) . This change allows HIV-infected Thai patients to receive early ART initiation and minimize the risk of immunological discordance. Nevertheless, if the patients present late to health care, i.e., at low CD4 cell counts, they should be closely monitored after initiation of ART.
The results of the present study have shown that history of loss to follow-up during ART was a risk factor for immunological discordance. This may be related to patients' imperfect adherence to ART. Intervention to improve the regularity of clinical visits for HIVinfected patients receiving ART is also important in the avoidance of immunological discordance. Of note, CDC staging, which was a significant factor in univariate analysis, was not included in the model of multivariate analysis because it was highly correlated with CD4 cell count, which was already included in the model. Patient history of receiving co-trimoxazole for prophylaxis was also highly correlated with CD4 cell count.
There is no solid evidence for the belief that PI-based regimens may have lower likelihood of immunological discordance. Some clinicians may switch ART regimen from NNRTI-based to PI-based in patients with immunological discordance. However, results from the present study show that type of ART regimens is not associated with immunological discordance. To date, there is no published data to support switching of ART regimens in patients with immunological discordance.
We recognize some limitations in the present study. First, by nature, retrospective study resulted lacks certain variables in some patients. Second, we screened cases based on lab results of patients who had CD4 cell count ＜ 200 cells/mm 3 which may not include patients of unknown CD4 level. Third, we cannot show the outcomes of immunological discordance, which may be potentially meaningful in the context of clinical decision-making. However, previous studies have clearly shown the evidence of increased risk of AIDS or death (5) (6) (7) (8) (9) . Lastly, our study may be limited by the relatively small number of patients. Nonetheless, the results provide relevant information regarding risks factors for immunological discordance among HIVinfected patients and could be useful for clinicians providing care to HIV-infected patients in resourcelimited settings.
In summary, our findings emphasize that low baseline CD4 cell count and history of loss to follow-up are risk factors for immunological discordance. Early initiation of ART at higher CD4 cell count and comprehensive intervention to improve regularity of clinic visit and adherence to ART are crucial to prevent immunological discordance among HIV-infected patients.
